Vol - 25, Issue - 7
About the Journal
[This article belongs to Volume - 25, Issue - 7]
International Medical Journal
Journal ID : IMJ-27-06-2020-522
Total View : 2

Abstract : It is challenging to treat flushing and persistent erythema of rosacea in spite of many topical and systemic treatment options. Recently, intradermal botulinum toxin injection has been used as a novel treatment for erythemato- telangiectatic rosacea. This study aims to evaluate the safety and efficacy of intra- dermal injection of Botulinum Toxin A (BTA) as a treatment for erythemato- telangiectactic rosacea ETR. A prospective study was done on patients with ETR treated with intra-dermal injections of BTA. Initial assessment of patients at baseline was documented then assessment of cases after injection was done using the five parameters of ETR severity scoring system The presence of the reported side effects were specifically assessed. A total 21 patients with ETR participated in the study. The mean age was 35.42 ± 9.43 year. The majority of patients (N=17, 81%) were noted to have significant improvement of their rosacea symptoms with treatment, the mean ETR score showed significant decrement from 8.48 to 4.64 over follow up visits with statistical significant (P = 0.001*). The compliance rate was 90%. None of the patients report any major side effects. Intradermal botulinum toxin injection considered a reasonable treatment modality for ETR. it is safe, effective and can provide reliable relief of long-lasting symptom of ETR. The procedure is well tolerated and provide a desirable alternative for daily topical treatments or systemic medications.

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
//